These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32302426)

  • 41. Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.
    Cheung MC; Hay AE; Crump M; Imrie KR; Song Y; Hassan S; Risebrough N; Sussman J; Couban S; MacDonald D; Kukreti V; Kouroukis CT; Baetz T; Szwajcer D; Desjardins P; Shepherd L; Meyer RM; Le A; Chen BE; Mittmann N;
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25868579
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mobilization of peripheral blood progenitor cells after DHAP regimen with or without rituximab: a large multicenter comparative study in patients with malignant lymphoma.
    de Latour RP; Chaoui D; Bourhis JH; Belhocine R; Park S; Legrand O; Brault P; Rio B; Heshmati F; Assouad S; Decaudin D
    Leuk Lymphoma; 2007 May; 48(5):897-904. PubMed ID: 17487733
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis.
    Olivieri A; Brunori M; Capelli D; Montanari M; Massidda D; Gini G; Lucesole M; Poloni A; Offidani M; Candela M; Centurioni R; Leoni P
    Eur J Haematol; 2004 Jan; 72(1):10-7. PubMed ID: 14962257
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
    Doorduijn JK; van Imhoff GW; van der Holt B; Schouten HC; Schaafsma MR; MacKenzie MA; Baars JW; Kersten MJ; Lugtenburg PJ; van den Bent MJ; Enting RH; Spoelstra FM; Poortmans P; Bromberg JEC
    Hematol Oncol; 2017 Dec; 35(4):497-503. PubMed ID: 27530779
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successful use of full-dose dexamethasone, high-dose cytarabine, and cisplatin as part of initial therapy in non-hodgkin and hodgkin lymphoma with severe hepatic dysfunction.
    McCarthy J; Gopal AK
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):167-70. PubMed ID: 19406729
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
    Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
    Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
    Harting R; Venugopal P; Gregory SA; O'brien T; Bogdanova E
    Clin Lymphoma Myeloma; 2007 May; 7(6):406-12. PubMed ID: 17621406
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group.
    Sasse S; Alram M; Müller H; Smardová L; Metzner B; Doehner H; Fischer T; Niederwieser DW; Schmitz N; Schäfer-Eckart K; Raemaekers JM; Schmalz O; Tresckow BV; Engert A; Borchmann P
    Leuk Lymphoma; 2016 May; 57(5):1067-73. PubMed ID: 26693800
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma.
    McLaughlin P; Velasquez WS; Redman JR; Yung WK; Hagemeister FB; Rodriguez MA; Cabanillas F
    J Natl Cancer Inst; 1988 Nov; 80(17):1408-12. PubMed ID: 3172268
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
    Josting A; Sieniawski M; Glossmann JP; Staak O; Nogova L; Peters N; Mapara M; Dörken B; Ko Y; Metzner B; Kisro J; Diehl V; Engert A
    Ann Oncol; 2005 Aug; 16(8):1359-65. PubMed ID: 15939712
    [TBL] [Abstract][Full Text] [Related]  

  • 53. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
    Shah NN; Szabo A; Huntington SF; Epperla N; Reddy N; Ganguly S; Vose J; Obiozor C; Faruqi F; Kovach AE; Costa LJ; Xavier AC; Okal R; Kanate AS; Ghosh N; Kharfan-Dabaja MA; Strelec L; Hamadani M; Fenske TS; Calzada O; Cohen JB; Chavez J; Svoboda J
    Br J Haematol; 2018 Feb; 180(4):534-544. PubMed ID: 29265182
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
    Josting A; Rudolph C; Mapara M; Glossmann JP; Sieniawski M; Sieber M; Kirchner HH; Dörken B; Hossfeld DK; Kisro J; Metzner B; Berdel WE; Diehl V; Engert A
    Ann Oncol; 2005 Jan; 16(1):116-23. PubMed ID: 15598948
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Osumi T; Mori T; Fujita N; Saito AM; Nakazawa A; Tsurusawa M; Kobayashi R
    Pediatr Blood Cancer; 2016 Oct; 63(10):1794-9. PubMed ID: 27314926
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation.
    Philip T; Chauvin F; Armitage J; Bron D; Hagenbeek A; Biron P; Spitzer G; Velasquez W; Weisenburger DD; Fernandez-Ranada J
    Blood; 1991 Apr; 77(7):1587-92. PubMed ID: 2009374
    [TBL] [Abstract][Full Text] [Related]  

  • 57. R-DHAP: a good small step, but not the journey's end.
    McLaughlin P; Vose JM
    Leuk Lymphoma; 2008 Jun; 49(6):1019-21. PubMed ID: 18452108
    [No Abstract]   [Full Text] [Related]  

  • 58. The impact of overweight on renal toxicity in patients treated with dexamethasone, high-dose cytarabine, and cisplatin.
    Umino K; Hatano K; Ochi SI; Genda H; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Nagayama T; Mashima K; Minakata D; Nakano H; Yamasaki R; Morita K; Yamamoto C; Ashizawa M; Sato K; Oh I; Fujiwara SI; Ohmine K; Muroi K; Kanda Y
    Int J Hematol; 2020 Mar; 111(3):396-400. PubMed ID: 31728828
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.
    Le Gouill S; Thieblemont C; Oberic L; Moreau A; Bouabdallah K; Dartigeas C; Damaj G; Gastinne T; Ribrag V; Feugier P; Casasnovas O; Zerazhi H; Haioun C; Maisonneuve H; Houot R; Jardin F; Van Den Neste E; Tournilhac O; Le Dû K; Morschhauser F; Cartron G; Fornecker LM; Canioni D; Callanan M; Béné MC; Salles G; Tilly H; Lamy T; Gressin R; Hermine O;
    N Engl J Med; 2017 Sep; 377(13):1250-1260. PubMed ID: 28953447
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in lymphoma.
    Kanat O; Ozet A; Ataergin S; Arpaci F; Kuzhan O; Komurcu S; Ozturk B; Ozturk M
    Med Princ Pract; 2010; 19(5):344-7. PubMed ID: 20639655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.